C12N 2710/16434
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16434 (Use of virus or viral component as vaccine) appears on 15 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 15
- Published applications
- 15
- Assignees
- 12
- Inventors
- 31
- Latest grant
- 3 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 4 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 1 | 2 |
| 2012 | 0 | 2 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
| 2025 | 0 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- Multivalent Kaposi sarcoma-associated herpesvirus-like particles and uses thereof3 Dec 2024US 12,156,911 B2City of Hope
- Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors19 Oct 2021US 11,149,255 B2BioVentures, LLC
- Method of enhancing KSHV LANA1 immunogenicity17 Jul 2018US 10,022,438 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Method of enhancing KSHV LANA1 immunogenicity2 Aug 2016US 9,402,895 B2University of Pittsburg—Of the Commonwealth System of Higher Education
- Lipoparticles comprising proteins, methods of making, and using the same15 Dec 2015US 9,213,027 B2Integral Molecular, Inc.
- Multivalent kaposi sarcoma-associated herpesvirus-like particles and uses thereof22 May 2025US 2025/0161435 A1City of Hope
- Mrna vaccine design via the alteration of codon usage2 Jan 2025US 2025/0000966 A1The Cleveland Clinic Foundation
- Multivalent kaposi sarcoma-associated herpesvirus-like particles and uses thereof12 May 2022US 2022/0143174 A1City of Hope
- Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors11 Jul 2019US 2019/0211313 A1BioVentures, LLC
- Method of Enhancing KSHV LANA1 Immunogenicity17 Nov 2016US 2016/0331833 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
Most cited
By later US patents
- Unique associated Kaposi's sarcoma virus sequences and uses thereof15US 5,801,042 AThe Trustees of Columbia University in the City of New York · 1998
- Unique associated Kaposi's sarcoma virus sequences and uses thereof15US 5,830,759 AThe Trustees of Columbia University in the City of New York · 1998
- Lipoparticles comprising proteins, methods of making, and using the same8US 9,213,027 B2Integral Molecular, Inc. · 2015
- Lipoparticles comprising proteins, methods of making, and using the same7US 8,574,590 B2Integral Molecular, Inc. · 2013
- Unique associated Kaposi's Sarcoma virus sequences and uses thereof6US 6,183,751 B2The Trustees of Columbia University in the City of New York · 2001